Evidence map›Paper›PMID 27292320›Full record

ArticleCancer medicine2016

Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.

Takehiko Fukuda, Takao Kamai, Akinori Masuda, Akinori Nukui, Hideyuki Abe, Kyoko Arai, Ken-Ichiro Yoshida

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06584435 (A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer), which is not on this map. Cited by 39 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 5 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06584435 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer

TypeinterventionalSponsorTianjin Medical University Second HospitalRan2022 to 2027Enrolled100ConditionsHigh-risk Renal Cell CarcinomaArmsToripalimab
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Takehiko FukudaDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Takao KamaiDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Akinori MasudaDialysis center, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
Akinori NukuiDepartment of Urology, Nasu Red Cross Hospital, Tochigi, Japan.
Hideyuki AbeDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Kyoko AraiDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Ken-Ichiro YoshidaDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Dokkyo Medical University · JPDokkyo Medical University Saitama Medical Center · JPYamaguchi Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is an immunogenic and proangiogenic cancer. Although antivascular endothelial growth factor (VEGF) therapies achieve impressive responses in some patients, many tumors eventually develop resistance to such therapy. The B7 family molecules such as CTLA-4, PD-1, and PD-L1 are pivotal players in immune checkpoints that positively or negatively regulate various immune responses. Recently, immunotherapy based on blocking immune checkpoints with anti-CTLA4, anti-PD-1, or anti-PD-L1 antibodies has been proposed as a potential new approach to the treatment of metastatic RCC. Higher expression of PD-L1 and B7-H4 in the tumors is associated with a poor prognosis in RCCs, however, the clinical impact of serum levels of B7 family molecules has not been elucidated in patients with metastatic RCCs receiving VEGF-targeted agents. We assessed the preoperative serum levels of B7 family molecules, including CD80, CD86, PD-1, PD-L1, B7-H3, B7-H4, and CTLA-4, and CD28 in RCC patients, and determined their relations with various clinicopathological characteristics. Elevated preoperative serum levels of PD-L1 and B7-H4 were correlated with less differentiated tumors, higher invasive and metastatic potential, a worse response to anti-VEGF therapy, and shorter overall survival. These findings suggested that investigating preoperative serum levels of PD-L1 and B7-H4 might not only be useful to assess the biological aggressiveness of RCCs, but also to predict the efficacy of anti-VEGF therapy and the eventual prognosis, indicating the future design of clinical trials of therapies targeting immune checkpoint in advanced RCCs.

Indexed as

AdultAgedAntineoplastic AgentsAxitinibB7-H1 AntigenBiomarkers, TumorCarcinoma, Renal CellCD28 AntigensChemotherapy, AdjuvantFemaleHumansImidazolesIndazolesIndolesKaplan-Meier EstimateKarnofsky Performance StatusAntineoplastic AgentsAxitinibB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCD28 AntigensImidazolesIndazolesIndolesNeoplasm ProteinsPyrrolesSunitinibVascular Endothelial Growth Factor AVEGFA protein, humanV-Set Domain-Containing T-Cell Activation Inhibitor 1VTCN1 protein, humanAxitinibB7 familyCD28-family receptorsimmune checkpointsreceptor tyrosine kinase inhibitorsrenal cell carcinomasunitinib

Identifiers

PMID27292320
PMCPMC4971909
OpenAlexW2411382228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.